Here we report a curcumin–artemisinin coamorphous solid (1 : 1) prepared by rotavaporization and a dramatic increase in the pharmacokinetic profile of curcumin (AUC0–12 2.6 μg h mL−1, Cmax 1 μg mL−1) administered as CUR–ART to SD rats. PXRD and FESEM analysis explains the molecular basis for the solubility enhancement of coamorphous CUR–ART.
